Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 12, n. 2, p. 77–85, 2011. DOI: 10.7175/fe.v12i2.73. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/73. Acesso em: 28 dec. 2025.